Goldman Sachs
CRDL

Goldman Sachs’s Cardiol Therapeutics CRDL Stock Holding History

Goldman Sachs’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$449K Buy
332,400
+3,900
+1% +$4K ﹤0.01% 5667
2025
Q4 		$313K Buy
328,500
+6,700
+2% +$7.02K ﹤0.01% 5844
2025
Q3 		$344K Buy
321,800
+264,300
+460% +$321K ﹤0.01% 5692
2025
Q2 		$78.2K Buy
57,500
+18,300
+47% +$21.3K ﹤0.01% 5864
2025
Q1 		$38K Buy
39,200
+3,300
+9% +$4.05K ﹤0.01% 5909
2024
Q4 		$46K Sell
35,900
-200
-0.6% -$337 ﹤0.01% 5847
2024
Q3 		$71.5K Buy
36,100
+12,600
+54% +$26.1K ﹤0.01% 5608
2024
Q2 		$47.5K Hold
23,500
– – ﹤0.01% 5473
2024
Q1 		$42.5K Hold
23,500
– – ﹤0.01% 5337
2023
Q4 		$19.8K Hold
23,500
– – ﹤0.01% 5445
2023
Q3 		$21K Hold
23,500
– – ﹤0.01% 5356
2023
Q2 		$20.9K Sell
23,500
-1,100
-4% -$726 ﹤0.01% 5542
2023
Q1 		$12K Sell
24,600
-76,900
-76% -$45.5K ﹤0.01% 5723
2022
Q4 		$51.8K Buy
+101,500
New +$61.9K ﹤0.01% 5591
2022
Q2 		– Sell
-65,600
Closed -$100K – 6491
2022
Q1 		$100K Sell
65,600
-60,500
-48% -$99.8K ﹤0.01% 6107
2021
Q4 		$233K Buy
126,100
+107,000
+560% +$296K ﹤0.01% 5812
2021
Q3 		$79K Buy
+19,100
New +$69.2K ﹤0.01% 5952

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs's CRDL Position: Q1 2026 in Review

Goldman Sachs increased its Cardiol Therapeutics (CRDL) stake by 1.2% in Q1 2026, buying an estimated $4K and bringing the position to 332,400 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #5667.

Goldman Sachs first reported a position in CRDL in Q3 2021 and has held it in 17 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Goldman Sachs held 332,400 shares of Cardiol Therapeutics worth $449K as of Q1 2026.
  • Goldman Sachs bought 3,900 Cardiol Therapeutics shares in Q1 2026, an estimated $4K.
  • Cardiol Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5667 holding.
  • Goldman Sachs first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.